Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Aqneursa (levacetylleucine)
- erlotinib
Interactions between your drugs
erlotinib levacetylleucine
Applies to: erlotinib, Aqneursa (levacetylleucine)
Levacetylleucine may increase the blood levels and effects of erlotinib. Talk to your doctor if you have any questions or concerns. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.
Drug and food interactions
erlotinib food
Applies to: erlotinib
Erlotinib should be taken on an empty stomach at least 1 hour before or 2 hours after a meal and at the same time each day unless otherwise directed by your doctor. You should also avoid grapefruit and grapefruit juice while taking erlotinib. Food and grapefruit juice can increase the absorption of erlotinib from the gastrointestinal tract, which may lead to higher blood levels of the medication and possibly increased side effects. If you are a smoker, you should try to quit as soon as you can. Cigarette smoking can reduce the blood levels of erlotinib, which may make the medication less effective in treating your cancer. It is best to avoid smoking during erlotinib therapy. Talk to a healthcare professional if you have any questions or concerns. If you start smoking or undergo smoking cessation, your doctor may need to adjust your dose of erlotinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Miplyffa
Miplyffa (arimoclomol) is a medication for Niemann-Pick disease type C (NPC) to help stop disease ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Cerdelga
Cerdelga (eliglustat) is used to treat mild to moderate Type 1 Gaucher Disease. Includes Cerdelga ...
Crysvita
Crysvita is used for familial hypophosphatemia, osteomalacia, X-Linked Hypophosphatemia
Galafold
Galafold (migalastat) is used to treat Fabry disease. Includes Galafold side effects, interactions ...
Givlaari
Givlaari injection is used for acute hepatic porphyria (AHP) to reduce the number of acute attacks ...
Iqirvo
Iqirvo (elafibranor) is used to treat primary biliary cholangitis (PBC) in combination with ...
Kuvan
Kuvan is used to help the body activate the enzyme needed to control blood levels of phenylalanine ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.